U.S. markets open in 4 hours 2 minutes
  • S&P Futures

    3,853.00
    +43.75 (+1.15%)
     
  • Dow Futures

    31,232.00
    +320.00 (+1.04%)
     
  • Nasdaq Futures

    13,113.50
    +202.50 (+1.57%)
     
  • Russell 2000 Futures

    2,249.20
    +50.00 (+2.27%)
     
  • Crude Oil

    62.39
    +0.89 (+1.45%)
     
  • Gold

    1,743.80
    +15.00 (+0.87%)
     
  • Silver

    26.91
    +0.47 (+1.76%)
     
  • EUR/USD

    1.2044
    -0.0044 (-0.36%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    24.88
    -4.01 (-13.88%)
     
  • GBP/USD

    1.3954
    +0.0031 (+0.22%)
     
  • USD/JPY

    106.7130
    +0.2110 (+0.20%)
     
  • BTC-USD

    47,262.09
    +1,843.09 (+4.06%)
     
  • CMC Crypto 200

    949.57
    +16.43 (+1.76%)
     
  • FTSE 100

    6,595.46
    +112.03 (+1.73%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesday, March 2, 2021, at 8:30 a.m. ET.

The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1034166. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able to connect.

A webcast replay will be available via the "Investors" tab on the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, participant code 1034166.

About GlycoMimetics, Inc.

GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy Designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223006084/en/

Contacts

Investors:
Shari Annes
Phone: 650-888-0902
Email: sannes@annesassociates.com

Media:
Jamie Lacey-Moreira
Phone: 410-299-3310
Email: jamielacey@presscommpr.com